Clinical Trials
36 trialsTAURUS
European Myeloma Network B.V.
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Peking University First Hospital
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
PETHEMA Foundation
KMM1910
Samsung Medical Center
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Beijing Chao Yang Hospital
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
SENSIB
University Hospital, Clermont-Ferrand
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Myeloma XI
University of Leeds
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CyBorD-Dara
National University of Ireland, Galway, Ireland
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
REBOUND
IRCCS Centro di Riferimento Oncologico della Basilicata
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase-0-MM
Aalborg University Hospital
MUKsix
University of Leeds
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Sun Yat-sen University
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
KMM-97
Chonnam National University Hospital
Bortezomib
Clinical Service, China
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Second Military Medical University
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Korean Multiple Myeloma Working Party
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
University of Wuerzburg